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The high human immunodeficiency virus (HIV) prevalence in sub-Saharan Africa has markedly changed the epidemiology and 
presentation of adult meningitis. We conducted a systematic review using PubMed, Embase, Ovid, CENTRAL, and African Index 
Medicus to identify studies in Africa with data on neurological outcomes in adults after meningitis. We found 22 articles meeting 
inclusion criteria. From 4 studies with predominately pneumococcal meningitis, a median of 19% of survivors experienced hearing 
loss up to 40 days. Two studies of cryptococcal meningitis evaluated 6- to 12-month outcomes; in one, 41% of survivors had global 
neurocognitive impairment and 20% severe impairment at 1 year, and in a second 30% of survivors had intermediate disability and 
10% severe disability at 6 months. A single small study of patients with tuberculosis/HIV found marked disability in 20% (6 of 30) at 
9 months. Despite the high burden of meningitis in sub-Saharan Africa, little is known about neurological outcomes of patients with 
HIV-associated meningitides.
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Meningitis is associated with high morbidity and mortality in 
resource-rich and resource-limited settings [1]. The human 
immunodeficiency virus (HIV) epidemic in sub-Saharan 
Africa (SSA) led to an increase in incidence of meningitis, 
especially in adults with advanced HIV disease [2, 3]. Case-
fatality estimates for 3 of the main causes of adult meningitis 
in SSA—cryptoccoccal, pneumococcal, and tuberculous men-
ingitis—range from 41% to 70%, and meningitis is the cause of 
up to 20% of deaths in HIV-infected cohorts [4–6]. In addition 
to the high mortality, ongoing disability from neurological 
sequelae in survivors further increases the burden of disease 
due to meningitis [7].
Multiple studies from Africa have reported neurological 
sequelae in pediatric survivors of meningitis [8]. Pediatric 
studies show an increased risk of mortality from bacterial men-
ingitis in HIV-infected versus uninfected children and greater 
risk of recurrence, suggesting that these patients are more sus-
ceptible to poor outcomes [9, 10]. However, the epidemiology 
and etiology of meningitis differs markedly between adults 
and children, and little is known about long-term outcomes of 
adult meningitis in Africa. From population-based estimates 
in rural Kenya, meningitis was one of the leading causes of 
disability-adjusted life years lost due to high case-fatality rates 
and long-term disability in HIV-uninfected survivors [7]. 
A clear understanding of long-term disability of adult menin-
gitis survivors in the context of the high regional burden of 
HIV-associated meningitis has important public health and 
economic implications for low- and middle-income countries 
[6, 11]. The aim of this systematic review is to describe our cur-




We conducted a systematic review of articles published on 
neurological sequelae of adult meningitis in Africa with no 
lower limit on start date until June 30, 2017. A search strategy 
was developed with 3 components: one identifying articles on 
“meningitis” or “meningoencephalitis,” a second limiting the 
search to articles from Africa, and a third identifying articles 
reporting on neurological sequelae of disease. We searched 5 
databases, including PubMed, Embase, Ovid, CENTRAL, and 
African Index Medicus. The full search strategy is shown in 
Table 1. Three reviewers (D. W. G., H. K. M., and M. W. T.) inde-
pendently screened the databases using these search terms. We 
identified relevant supplemental articles through review of ref-
erence lists of relevant articles (published reviews and included 
studies) in the primary search. Citations were uploaded into an 
EndNote Library and duplicate articles were removed.
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Citation Screening (Inclusion/Exclusion Criteria)
We screened citations against standardized eligibility cri-
teria with initial title and abstract search followed by full 
text review of potentially eligible articles. Inclusion criteria 
included the following: (1) involving patients ≥12  years of 
age; (2) conducted at health centers in Africa; (3) reporting 
on prevalence or incidence of any neurologic sequelae in 
patients with meningitis; and (4) using a prospective or ret-
rospective observational cohort methodology or randomized 
controlled trials. We excluded case studies and case series 
with less than 20 patients, because of concern for heteroge-
neity of reported outcomes and high likelihood of publica-
tion of nonrepresentative cases in case reports or case series, 
as well as published conference abstracts. For studies with 
pediatric and adult outcomes data separately reported, we 
excluded pediatric patients in our analysis. Adult and pedi-
atric meningitis outcome data were intermixed in several 
included studies, primarily studies of Neisseria meningitidis 
meningitis. Inclusion of patients ≥12 years of age was decided 
as a developmentally meaningful cutoff (following rapid neu-
rodevelopmental change, particularly in the first decade of 
life). We included studies reporting outcomes from micro-
biologically confirmed meningitis or meningitis diagnosed 
using molecular methods, and we also included studies with 
cases diagnosed using a combination of microbiological and/
or molecular methods and cerebrospinal fluid (CSF) profiles 
suggestive of bacterial meningitis (CSF with polymorphonu-
clear cell pleocytosis), as well as N meningitidis diagnosed 
clinically during meningococcal meningitis epidemics. No 
language restrictions were placed on the search. Although no 
formal quality criteria were used to determine inclusion or 
exclusion of articles, we undertook a subjective assessment of 
trial quality based on established guidelines [12].
Data Abstraction and Analysis
Study information was entered into Microsoft Excel spread-
sheets, and accuracy was verified through consensus from 
all authors. Study year(s), country and clinical setting, study 
design, meningitis pathogen(s), patient clinical characteris-
tics (age distribution and HIV status), follow-up period, out-
comes measured, and outcomes data including both death and 
neurological sequelae were entered into spreadsheets (Table 2 
and Table 3). We categorized outcomes according to common 
sequelae, eg, hearing loss, as performed in previous meningitis 
reviews [8, 13]. Tables were organized by main causative patho-
gen and further sorted by year of publication.
No formal meta-analysis was undertaken due to the small 
number of studies meeting inclusion criteria as well as heter-
ogeneity in causative pathogen, follow-up period, and neuro-
logical sequelae evaluated. Descriptive statistics were used to 
analyze outcomes using percentage, median and interquar-
tile range, mean and standard deviation, or other descriptive 
measures as indicated. We did not report pooled neurological 
sequelae of individual studies due to significant heterogeneity 
in types of sequelae evaluated, method of sequelae evaluation 
between studies, and limited number of studies for most major 
causative pathogens.
RESULTS
Literature Search and Citation Screening
The search yielded 6204 original articles for review on June 
30, 2017. The database was deduplicated, and then a primary 
screen by article title was executed (Figure  1); 3241 articles 
were excluded at this point. Most references were screened 
out because they contained data in neonatal and/or pediat-
ric populations or described case studies or small case series. 
A secondary screening of full abstracts was then conducted in 
Table 1. PubMed Search Terms
Search component 1 [meningitis OR meningoencephalitis]
Search component 2 [Africa OR African OR Algeria OR Algerian OR Angola OR Angolan OR Benin OR Beninese OR Beninoise OR Botswana 
OR Botswanan OR Motswana OR Batswana OR Burkina Faso OR Burkinabe OR Burundi OR Burundian OR Cameroon 
OR Cameroonian OR cape Verde OR cape Verdean OR cab Verdeans OR central African republic OR central African OR 
chad OR Chadian OR Comoros OR Comorian OR democratic republic of the Congo OR Congolese OR republic of the 
Congo OR congo-brazzaville OR cote d’ivoire OR ivory coast OR Ivorian OR Ivoirian OR Djibouti OR Djiboutian OR Egypt 
OR Egyptian OR equatorial guinea OR equatorial guinean OR Equatoguinean OR Eritrea OR Eritrean OR Ethiopia OR 
Ethiopian OR Gabon OR Gabonese OR Gambia OR Gambian OR Ghana OR Ghanaian OR guinea OR Guinean OR Guinea- 
Bissau OR Bissau OR Kenya OR Kenyan OR Lesotho OR Basotho OR Mosotho OR Libya OR Libyan OR Madagascar 
OR Malagasy OR Malawi OR Malawian OR Mali OR Malian OR Mauritania OR Mauritanian OR Mauritius OR Mauritian 
OR Mayotte OR Mahuran OR morocco OR Moroccan OR Mozambique OR Mozambican OR Namibia OR Namibian OR 
Niger OR nigerien OR Nigeria OR Nigerian OR Rwanda OR Rwandan OR Rwandese OR Senegal OR Senegalese OR 
Seychelles OR Seychellois OR seychelloise OR sierra Leone OR sierra Leonean OR Somalia OR Somali OR south Africa 
OR south African OR Sudan OR Sudanese OR Swaziland OR Swazi OR Tanzania OR Tanzanian OR Togo OR Togolese 
OR Tunisia OR Tunisian OR Uganda OR Ugandan OR western Sahara OR western Saharan OR Zambia OR Zambian OR 
Zimbabwe OR Zimbabwean]
Search component 3 [cognitive OR cognition OR neurocognitive OR neurocognition OR complications OR attention OR behavior OR behavioral 
OR behaviors OR sequelae OR impairment OR retardation OR epilepsy OR disorder OR learning OR memory OR func-
tion OR functions OR functional OR dysfunction OR dysfunctional OR dysfunctions OR deficit OR neuropsychological OR 
psychological OR psychomotor OR motor OR hyperactivity OR disability OR disabilities OR iq OR intelligence OR hearing 
OR sensorineural OR deaf OR deafness OR “rankin scale”]
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which a further 943 articles were excluded for not including 
data on neurological outcomes. In articles that did not include 
abstracts, we reviewed full-text articles. Three additional review 
articles were identified, and relevant references from these 
reviews were included in the final article list [8, 14, 15]. Full 
text of the remaining 380 articles was obtained and each article 
was reviewed. Of these, 22 met all inclusion criteria and were 
included in the final review.
Articles in the Review
We identified 22 articles meeting inclusion criteria with 12 
African countries represented (Figure  2). In all but 1 study, 
patients were treated for meningitis in hospital settings, with 
treatment provided at referral centers in 17 studies. The only 
or predominate cause of meningitis was nontuberculous bac-
terial in 16 studies, Mycobacterium tuberculosis in 2 studies, and 
Cryptococcus in 4 studies.
Four studies were published at a single referral hospital/US 
Navy research unit in Egypt [16–19] and 2 at a single referral 
hospital in Senegal [20, 21], both countries with a low HIV prev-
alence. Three studies were published from a single large referral 
hospital in Malawi with predominately HIV-infected patients 
(84%–100% HIV prevalence) [22–24]. Follow-up duration was 
variable: 8 of the 22 studies presented only in-hospital neurolog-
ical sequelae of survivors, and follow-up for the remaining 14 
studies ranged from 1 month to 2 years. Twelve articles were pro-
spective cohort studies, 5 were retrospective cohort studies, and 5 
were prospective randomized-controlled trials (RCTs) [Table 2].
Neisseria meningitidis Meningitis
Neisseria meningitidis was the principle pathogen identified in 9 
bacterial studies with 2718 patients. Neisseria meningitidis was 
the only pathogen isolated from 6 studies. Penicillin or ampi-
cillin and/or chloramphenicol were used to treat patients in 
most studies. Only 1 study [25] gave any information on HIV 
serostatus and reported low prevalence. Follow-up ranged from 
in-hospital to a 2-year follow-up of survivors. Males constituted 
56% (1529 of 2718) of patients (Table 2).
Ascertainment of adult outcomes was imperfect because most 
(8 of 9) studies included both adult and pediatric patients with-
out separation by age category. Mortality data were included in 
5 studies and ranged from 3% to 21% (median 13%). In men-
ingitis survivors, hearing loss (8 studies) and motor deficits (5 
studies) were the most commonly reported neurological seque-
lae. Any hearing loss was found in 2%–31% of patients (median 
5%) with severe/profound hearing loss reported in 2%–10% 
of patients (median 3%). Motor deficits were variably defined 
and ranged from 1% to 13% (median 2%) in 5 studies with 
moderate-to-severe disability (eg, hemiplegia/hemiparesis) in 
1%–2% (median 2%) from 3 studies. One study reported 6% 
of patients with moderate-to-severe visual loss and 3% with 
moderate-to-severe neurocognitive deficit at evaluation 6 to 
12 months after the meningitis episode (Table 3).
Steptococcus pneumoniae and Other Bacterial Meningitides
Five studies including 772 patients reported on neurological 
outcomes with Streptococcus pneumoniae as the single or most 
commonly confirmed pathogen. Streptococcus pneumoniae was 
the only pathogen in 1 study [21], was identified in 65% of cases 
in 1 study limited to microbiologically confirmed cases [26], 
and was isolated in 29%–56% of cases from 3 studies with a large 
percentage of cases diagnosed by CSF cellular profile [22, 23, 
27]. Treatment differed between studies, and adjunctive dexa-
methasone was used for a subgroup of patients in only 2 studies 
[23, 26]. Human immunodeficiency virus prevalence was high 
across studies, between 12% and 90%. Follow-up ranged from 
in-hospital to 40 days. Males constituted 53% (400 of 751) of 
cases (Table 2).
Two prospective RCTs from Malawi of primarily HIV-infected 
adult patients were high quality with the remaining studies of rel-
atively poor quality [22, 23]. Reported case-fatality rate ranged 
from 17% to 70% (median 54%). In the 2 Malawian prospective 
RCTs with mostly HIV-infected adults, mortality ranged from 
49% to 54% overall and 39% to 51% in cases of proven pneumo-
coccal meningitis, all managed with ceftriaxone (±dexametha-
sone). Hearing loss was reported to affect 3%–34% (median 
19%) of patients in 4 studies, with severe/profound hearing loss 
reported in 4%–34% (median 12%) of patients in 3 studies. Motor 
deficits were reported at 8%–32% in 2 studies, with no other out-
come documented in more than a single study (Table 3).
The 2 Malawian studies with predominately HIV-infected 
patients reported high rates of neurological sequelae in survi-
vors [22, 23]. In Ajdukiewicz et al [22], 22% (14 of 63) survivors, 
with or without pneumococcal disease, remained in a persis-
tent vegetative state (Glasgow Outcome Score 2) at 40 days. In 
Scarborough et al [23], 23% (47 of 202) of 40-day survivors and 
29% (38 of 130) of those with proven pneumococcal meningitis 
had 1 or more neurological sequelae (blindness, debility, com-
plete deafness, intellectual impairment, paresis, or recurrent 
seizures).
One retrospective cohort study from Egypt evaluated neu-
rological sequelae in 95 patients with microbiologically con-
firmed, Gram-negative, bacillary meningitis [17]. This study 
included both adults and children and did not include data on 
HIV status. The case-fatality rate was 29% (28 of 95), and the 
rate of pooled in-hospital sequelae (cerebral damage, hearing 
loss, hemiplegia, hydrocephalus, optic atrophy, and/or seizure 
disorder) in survivors was 39% (26 of 67). Six percent (4 of 
67) of survivors had hearing loss, 7% (5 of 67) had hemiplegia, 
7% (5 of 67) had seizure disorder, and 9% (6 of 67) had optic 
atrophy. Another study from Egypt included patients with a mix 
of microbiologically confirmed bacterial meningitis and tuber-
culous meningitis [28]. At hospital discharge, 43% (13 of 30) of 
survivors with bacterial meningitis and 45% (5 of 11)  with 
tuberculous meningitis had severe disability determined by 
Glasgow Outcomes Scale score.
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Cryptococcal Meningitis
Four articles evaluated neurological sequelae of HIV-infected 
adult patients with cryptococcal meningitis [24, 29–31]. One 
good-quality study from Uganda reported global neurocogni-
tive dysfunction, defined as mean composite score of multi-
domain neurocognitive testing at least 1 standard deviation 
below that of HIV-uninfected Ugandans (z-score < −1), seri-
ally over 1  year in cryptococcal meningitis survivors who 
received amphotericin-based induction therapy. At 1 month, 
89% (69 of 78) of survivors had impaired neurocognitive func-
tion. This improved to 41% (26 of 64) at 1 year [29]. Meningitis 
survivors had only slightly higher disability compared with 
HIV-infected Ugandans without a prior history of neurolog-
ical infection. The case-fatality rate for patients who lived to 
1 month was 12% (9 of 78) at 1 year; 5 of those patients died 
before a 1-month follow up, and 3 patients died before the 
6-month follow up. A second study from the same prospective 
RCT reported additional 1-month neurocognitive outcomes 
[32]. At 1 month, 92% of survivors had an International HIV 
Dementia Scale score ≤10, suggesting possible HIV-associated 
neurocognitive disorder. Six-month neurocognitive outcomes 
from another quality large prospective RCT found that 20% 
of survivors had severe disability at 10 weeks and 10% at 
6 months, defined as answering yes to the question “Does the 
patient require help from anybody for everyday activities?” 
or with a Modified Rankin Scale score of ≥3 (symptoms that 
restrict lifestyle and prevent totally independent living) [30]. 
Of note, this study included patients from countries in both 
Africa (Malawi and Uganda) and Asian countries, but neu-
rocognitive outcomes were not disaggregated by country. We 
also excluded patients receiving experimental dexamethasone 
therapy, which was associated with higher rates of mortal-






























Figure 1. Diagram of literature search.
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Tuberculosis Meningitis
We included 2 articles with 891 patients with sequelae data 
for tuberculosis meningitis. One high-quality but small study 
with 34 antiretroviral therapy (ART)-naive HIV-infected adults 
with tuberculous meningitis (confirmed or suspected) evalu-
ated patients for tuberculosis-associated immune reconstitu-
tion inflammatory syndrome (TB-IRIS) after ART initiation. 
The case-fatality rate was 12% (4 of 34) at 9 months, with all 
deaths occurring in patients with TB-IRIS at time points of 33, 
53, 60, and 118 days after tuberculous meningitis diagnosis. Of 
9-month survivors, 20% (6 of 30) had marked disability: 20% (6 
of 30) cognitive impairment (5 of 6 marked impairment defined 
as HIV dementia scale score <10), 7% (2 of 30) hemiparesis, and 
3% (1 of 30) hearing loss [33]. A second study from a referral 
hospital in Egypt reported outcomes in a large cohort of patients 
treated for tuberculous meningitis over 2 decades (1976–1996) 
[19]. This study included adults and children together, and 
no patients were known to be HIV-infected. Patients received 
3-drug antituberculous therapy for 2  years, during which 
period they were serially assessed for neurological sequelae. In 
total, 57% (490 of 857) of patients died and 30% (111 of 367) of 
patients survived with severe neurological sequelae (including 
cranial nerve palsy 5% [20 of 367], hemiparesis-paraplegia 5% 
[20 of 367], and hydrocephalus 8% [30 of 367]).
DISCUSSION
In our systematic review of neurological sequelae of adult men-
ingitis in Africa, we identified 22 articles with neurological 
sequelae outcome data in meningitis survivors. This included 
12 studies in counties with high HIV prevalence. These studies, 
published over a more than 35-year period, provide limited data 
showing high rates of postmeningitis disability in adult men-
ingitis survivors from resource-limited settings, particularly 
in those with HIV coinfection. More importantly, they reveal 
the paucity of high-quality data regarding the frequency and 
spectrum of neurological sequelae after adult meningitis from 
prospective studies, and they provide insight into gaps in our 
current understanding of long-term disability of adult meningi-
tis survivors. Accurate data regarding the long-term outcomes 
in adult meningitis survivors are essential for accurate estimates 
of disease burden and, given the frequency of adult meningitis 
in Africa, have broad public health and economic implications.
Our review highlights that little is known about long-term 
neurological sequelae in survivors of HIV-associated crypto-
coccal meningitis and tuberculous meningitis, 2 of the principle 
causes of adult meningitis in sub-Saharan Africa. Two articles 
included Ugandan patients from a single prospective RCT 
[29, 32]. As in prior studies in the region, acute mortality was 
































Figure 2. Origin of studies included in review and estimated human immunodeficiency virus prevalence.
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found significant impairment in the early weeks after incident 
cryptococcal meningitis, with Montgomery et al [32] reporting 
92% of survivors with an International AIDS Dementia Scale 
score suggestive of neurocognitive impairment, compared with 
66% of HIV-infected controls without meningitis. With longer 
follow-up, Carlson et  al [29] reported persistent neurocogni-
tive deficits in approximately half of survivors at 1  year. The 
relationship between this long-term neurocognitive impair-
ment and cryptococcal meningitis remains unclear. Although 
cryptococcal meningitis survivors also showed worse neuro-
cognitive function compared with HIV-infected Ugandans, 
these differences were small by 1 year of follow-up, and the con-
trol patients generally had less advanced HIV disease (mostly 
stage II and III) [29]. Neurocognitive deficits may have been 
a consequence of meningitis and/or other contributing fac-
tors, such as HIV-associated neurocognitive disorder [39, 40]. 
The choice of comparator also limits inferential reasoning and 
could be strengthened in this and other studies evaluating neu-
rocognitive domains with alternative comparator groups, such 
as HIV-infected populations started early on ART. A  second 
multicountry prospective RCT conducted in African and Asian 
countries found that 20% and 10% of survivors reported requir-
ing help with everyday activities at 10 weeks and 6  months, 
respectively [30]. Taken together, these data suggest signifi-
cant impairment early after incident cryptococcal meningitis, 
a period during which adherence to ART and continuation of 
fluconazole maintenance therapy are critical to prevent crypto-
coccal meningitis relapse and for overall survival.
Five studies described neurological sequelae in adult menin-
gitis with S pneumoniae, the most common cause of bacterial 
meningitis in HIV-infected adults, as the predominate patho-
gen [2, 41]. Two of these studies [22, 23], both from Malawi, 
consisted largely of HIV-infected adults and found approxi-
mately half of patients died of meningitis with one quarter of 
survivors left with severe disability, such as with persistent veg-
etative states or hemiparesis. These adverse outcomes are sig-
nificantly higher than rates of death and disability reported in 
resource-rich countries with low HIV prevalence, but they are 
more reflective of African pediatric populations [8, 14]. These 
data also likely underestimated the impact of pneumococcal 
meningitis in HIV-infected African cohorts because patients 
were enrolled in controlled clinical trials at a large referral 
hospital and given highly effective antibiotic therapy with cef-
triaxone. Because follow up was limited to 40 days, they may 
also have underestimated delayed outcomes such as epilepsy 
[42]. Unfortunately, in Africa, pneumococcal vaccination has 
demonstrated mixed efficacy for reducing invasive pneumococ-
cal disease, and dexamethasone therapy has not been associated 
with lower mortality or neurological sequelae in HIV-infected 
adults [23, 43, 44]. The best method for reduction in risk of 
incident disease and associated neurological sequelae is early 
HIV recognition and initiation of ART coupled with timely and 
appropriate antibiotic therapy [41].
Our review has several important limitations. First, case 
definitions, outcome measures, and means of assessment were 
highly variable between studies. A lack of validated neurocog-
nitive and limited neurological function assessments created 
very heterogeneous data and prevented formal meta-analy-
sis. Second, follow-up periods differed considerably with only 
approximately half of studies reporting outcomes after hospital 
discharge to characterize clinical evolution of disease. Third, 
because there were few studies evaluating outcomes in crypto-
coccal and tuberculous meningitis, no firm conclusions could 
be drawn about neurological outcomes in survivors but rather 
emphasizes the need for future studies, especially prospective 
cohort studies, to include multidomain measures of neuro-
logical outcomes of disease. Finally, for most studies involving 
meningococcal meningitis, neurological sequelae of pediatric 
and adult cases were not reported separately, which limited 
our ability to make firm conclusions about adult outcomes. In 
this mixed population, however, death and disability was sig-
nificantly lower than in cases of pneumococcal meningitis, as 
reported elsewhere [14].
CONCLUSIONS
In conclusion, although settings with high HIV prevalence in 
Africa have both a high incidence of meningitis and early mor-
tality, long-term sequelae in adult survivors remains poorly 
characterized. Limited data suggest high rates of neurological dis-
ability associated with HIV-related pneumococcal and TB men-
ingitis. Little is known about neurological sequelae in survivors 
of HIV-associated cryptococcal meningitis, although studies sug-
gest extremely high prevalence of neurocognitive and functional 
impairment in the early weeks after incident disease. Furthermore, 
long-term multidomain testing of neurological outcomes for sur-
vivors of HIV-associated cryptococcal meningitis and TB menin-
gitis is warranted. Tools need to be chosen carefully and consider 
challenges with repeat testing, such as risk of learner bias.
There is a need for improved understanding of neurological 
sequelae of adult meningitis in Africa. Pneumococcal meningi-
tis in the setting of high HIV prevalence confers a high risk of 
both death and severe neurological sequelae in survivors. Little 
is published on sequelae from HIV-associated cryptococcal or 
tuberculous meningitis, highlighting an urgent need to more 
accurately define outcomes of survivors in future studies.
Acknowledgments
Financial suppport. This work was funded by University of 
Pennsylvania Center for AIDS Research Grant P30 AI 045008 (to J. N. J.).
Potential conflicts of interest. All authors: No reported conflicts of 
interest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest Conflicts that the editors consider relevant to 
the content of the manuscript have been disclosed.
Downloaded from https://academic.oup.com/ofid/article-abstract/5/1/ofx246/4617690
by London School of Hygiene & Tropical Medicine user
on 15 January 2018
16 • OFID • Goldberg et al
References
1. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and anti-
microbial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 
23:467–92.
2. Jarvis JN, Meintjes G, Williams A, et al. Adult meningitis in a setting of high HIV 
and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010; 
10:67.
3. Thwaites GE, Duc Bang N, Huy Dung N, et al. The influence of HIV infection 
on clinical presentation, response to treatment, and outcome in adults with 
Tuberculous meningitis. J Infect Dis 2005; 192:2134–41.
4. Jarvis JN, Bicanic T, Loyse A, et  al. Determinants of mortality in a combined 
cohort of 501 patients with HIV-associated cryptococcal meningitis: implications 
for improving outcomes. Clin Infect Dis 2014; 58:736–45.
5. Wall EC, Cartwright K, Scarborough M, et al. High mortality amongst adoles-
cents and adults with bacterial meningitis in sub-Saharan Africa: an analysis of 
715 cases from Malawi. PLoS One 2013; 8:e69783.
6. Rajasingham R, Smith RM, Park BJ, et  al. Global burden of disease of HIV-
associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 2017; 
17:873–81.
7. Etyang AO, Munge K, Bunyasi EW, et al. Burden of disease in adults admitted to 
hospital in a rural region of coastal Kenya: an analysis of data from linked clinical 
and demographic surveillance systems. Lancet Glob Health 2014; 2:e216–4.
8. Ramakrishnan M, Ulland AJ, Steinhardt LC, et al. Sequelae due to bacterial men-
ingitis among African children: a systematic literature review. BMC Med 2009; 
7:47.
9. Molyneux EM, Tembo M, Kayira K, et al. The effect of HIV infection on paediat-
ric bacterial meningitis in Blantyre, Malawi. Arch Dis Child 2003; 88:1112–8.
10. Madhi SA, Madhi A, Petersen K, et al. Impact of human immunodeficiency virus 
type 1 infection on the epidemiology and outcome of bacterial meningitis in 
South African children. Int J Infect Dis 2001; 5:119–25.
11. Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national inci-
dence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a 
systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 
384:1005–70.
12. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 
4:1.
13. Lucas MJ, Brouwer MC, van de Beek D. Neurological sequelae of bacterial men-
ingitis. J Infect 2016; 73:18–27.
14. Edmond K, Clark A, Korczak VS, et  al. Global and regional risk of disabling 
sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet 
Infect Dis 2010; 10:317–28.
15. Woldeamanuel YW, Girma B. A 43-year systematic review and meta-analy-
sis: case-fatality and risk of death among adults with tuberculous meningitis in 
Africa. J Neurol 2014; 261:851–65.
16. Habib RG, Girgis NI, Yassin MW, et al. Hearing impairment in meningococcal 
meningitis. Scand J Infect Dis 1979; 11:121–3.
17. Hammad OM, Hifnawy TM, Omran DA, et al. Gram-negative bacillary meningi-
tis in Egypt. J Egypt Public Health Assoc 2011; 86:16–20.
18. Girgis NI, Farid Z, Mikhail IA, et al. Dexamethasone treatment for bacterial men-
ingitis in children and adults. Pediatr Infect Dis J 1989; 8:848–51.
19. Girgis NI, Sultan Y, Farid Z, et  al. Tuberculosis meningitis, Abbassia Fever 
Hospital-Naval Medical Research Unit No. 3-Cairo, Egypt, from 1976 to 1996. 
Am J Trop Med Hyg 1998; 58:28–34.
20. Seydi M, Soumare M, Sow AI, et  al. [Clinical, bacteriological and therapeutic 
aspects of meningococcal meningitis in Dakar in 1999]. Med Trop (Mars) 2002; 
62:137–40.
21. Manga NM, Ndour CT, Diop SA, et  al. [Adult purulent meningitis caused by 
Streptococcus pneumoniae in Dakar, Senegal]. Med Trop (Mars) 2008; 68:625–8.
22. Ajdukiewicz KM, Cartwright KE, Scarborough M, et al. Glycerol adjuvant ther-
apy in adults with bacterial meningitis in a high HIV seroprevalence setting in 
Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis 2011; 
11:293–300.
23. Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial menin-
gitis in adults in sub-Saharan Africa. N Engl J Med 2007; 357:2441–50.
24. Rothe C, Sloan DJ, Goodson P, et al. A prospective longitudinal study of the clin-
ical outcomes from cryptococcal meningitis following treatment induction with 
800 mg oral fluconazole in Blantyre, Malawi. PLoS One 2013; 8:e67311.
25. Heyman SN, Ginosar Y, Niel L, et al. Meningococcal meningitis among Rwandan 
refugees: diagnosis, management, and outcome in a field hospital. Int J Infect Dis 
1998; 2:137–42.
26. Okome-Nkoumou M, Loembe PM. Bacterial meningitis in the adult. Study of 
85 cases observed in the infectious disease unit of the Fondation Jeanne Ebori 
(F.J.E.), Libreville, Gabon. Bull Soc Pathol Exot 1999; 92:288–91.
27. Ford H, Wright J. Bacterial meningitis in Swaziland: an 18  month prospective 
study of its impact. J Epidemiol Community Health 1994; 48:276–80.
28. El-Gindy EM, Ali-Eldin FA, Bayoumy I, et al. Cognutuve and neurological com-
plications of bacterial meningitis in adult patients: a hospital based study. J Egypt 
Soc Parasitol 2015; 45:477–84.
29. Carlson RD, Rolfes MA, Birkenkamp KE, et  al. Predictors of neurocognitive 
outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective 
cohort study. Metab Brain Dis 2014; 29:269–79.
30. Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-
associated cryptococcal meningitis. N Engl J Med 2016; 374:542–54.
31. Montgomery MP, Nakasujja N, Morawski BM, et al. Neurocognitive function in 
HIV-infected persons with asymptomatic cryptococcal antigenemia: a compari-
son of three prospective cohorts. BMC Neurol 2017; 17:110.
32. Montgomery MP, Nakasujja N, Morawski BM, et al. Neurocognitive function in 
HIV-infected persons with asymptomatic cryptococcal antigenemia: a compari-
son of three prospective cohorts. BMC Neurol 2017; 17:110.
33. Marais S, Meintjes G, Pepper DJ, et  al. Frequency, severity, and prediction of 
tuberculous meningitis immune reconstitution inflammatory syndrome. Clin 
Infect Dis 2013; 56:450–60.
34. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after 
diagnosis of cryptococcal meningitis. N Engl J Med 2014; 370:2487–98.
35. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and 
outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-ex-
perienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 
2007; 45:76–80.
36. Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activ-
ity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs 
given in combination with amphotericin B for the treatment of HIV-associated 
cryptococcal meningitis. Clin Infect Dis 2012; 54:121–8.
37. Muzoora CK, Kabanda T, Ortu G, et al. Short course amphotericin B with high 
dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 2012; 
64:76–81.
38. Jackson AT, Nussbaum JC, Phulusa J, et al. A phase II randomized controlled trial 
adding oral flucytosine to high-dose fluconazole, with short-course amphotericin 
B, for cryptococcal meningitis. AIDS 2012; 26:1363–70.
39. McCombe JA, Vivithanaporn P, Gill MJ, Power C. Predictors of symptomatic 
HIV-associated neurocognitive disorders in universal health care. HIV Med 
2013; 14:99–107.
40. Abassi M, Morawski BM, Nakigozi G, et al. Cerebrospinal fluid biomarkers and 
HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, 
Uganda. J Neurovirol 2017; 23:369–75.
41. Domingo P, Suarez-Lozano I, Torres F, et  al. Bacterial meningitis in HIV-1-
infected patients in the era of highly active antiretroviral therapy. J Acquir 
Immune Defic Syndr 2009; 51:582–7.
42. Annegers JF, Hauser WA, Beghi E, et al. The risk of unprovoked seizures after 
encephalitis and meningitis. Neurology 1988; 38:1407–10.
43. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccha-
ride vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and 
placebo controlled trial. Lancet 2000; 355:2106–11.
44. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal 
conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812–22.
45. Coldiron ME, Salou H, Sidikou F, et al. Case-fatality rates and sequelae resulting 
from Neisseria meningitidis serogroup C epidemic, Niger, 2015. Emerg Infect Dis 
2016; 22:1827–9.
46. Jusot JF, Tohon Z, Yazi AA, Collard JM. Significant sequelae after bacterial men-
ingitis in Niger: a cohort study. BMC Infect Dis 2013; 13:228.
47. Hodgson A, Smith T, Gagneux S, et al. Survival and sequelae of meningococcal 
meningitis in Ghana. Int J Epidemiol 2001; 30:1440–6.
48. Fekade D, Zawde D. Epidemic meningococcal meningitis in adult Ethiopians in 
Addis Abeba, Ethiopia, 1988. Ethiop Med J 1992; 30:135–42.
49. Smith AW, Bradley AK, Wall RA, et al. Sequelae of epidemic meningococcal men-
ingitis in Africa. Trans R Soc Trop Med Hyg 1988; 82:312–20.
Downloaded from https://academic.oup.com/ofid/article-abstract/5/1/ofx246/4617690
by London School of Hygiene & Tropical Medicine user
on 15 January 2018
